Skip to content
Open access

The R120G Knock-in Mutation in αB-Crystallin is Insufficient to Induce Cardiomyopathy in Mice

Jul 2026 · American Journal of Physiology. Heart and Circulatory Physiology · Vol 331, pp. H588 - H596 · 0 citations
Medicine

TL;DR

Findings indicate that, within the age range examined, the CryABR120G KI model does not reproduce the overt cardiomyopathic phenotype associated with the CRYABR120G mutation in patients.

Abstract

Alpha B-crystallin (CryAB) is a small heat-shock protein highly expressed in cardiac tissue, where it functions as a molecular chaperone that helps prevent protein aggregation, particularly under stress conditions. A missense mutation in CryAB (R120G) causes autosomal dominant cardiomyopathy in humans and is characterized by extensive protein aggregation in cardiomyocytes. To better understand the pathogenic mechanisms underlying CryABR120G-associated cardiomyopathy, appropriate in vivo models are essential. Genetic mouse models are valuable tools for investigating disease pathogenesis and evaluating potential therapeutic strategies. In this study, we characterized a homozygous CryABR120G knock-in (KI) mouse model to assess the impact of this mutation on cardiac function. CryABR120G KI mice exhibited no overt changes in cardiac structure and function up to 12 months of age, with minimal changes in cardiac and proteotoxic stress markers, except for an increased atrial natriuretic peptide expression at 12 months. Protein quality control pathways remained largely unchanged. Although mitochondrial respiration was normal in young CryABR120G KI mice, it was reduced at 12 months of age. Despite the presence of insoluble protein aggregates, homozygous CryABR120G KI mice did not develop overt structural or functional cardiomyopathy through 12 months of age. These findings indicate that, within the age range examined, the CryABR120G KI model does not reproduce the overt cardiomyopathic phenotype associated with the CRYABR120G mutation in patients.

Read PDF

Similar papers

Open access Jul 2026

The SMYD1 p.Asn101Ser is a partial loss-of-function variant that impairs mitochondrial function and leads to early-onset cardiomyopathy

The first functional characterization of the cardiomyopathy-associated SMYD1 N101S variant identified in a child with severe infantile cardiomyopathy is provided, establishing a mechanistic link between SMYD1 dysfunction and infantile cardiomyopathy and highlighting the importance of integrating genomic and functional...

Marta W. Szulik, Clint Gwynn, Magnus Creed et al. · 0 citations
Open access Aug 2026

Alpha protein kinase 3 gene therapy restores heart function in mouse and human models of cardiomyopathy

It is demonstrated that adeno-associated virus-mediated delivery of full-length human ALPK3 prevents cardiomyopathy in neonatal mouse models and reverses established disease in adult mice, restoring cardiac structure, function and proteostasis, as well as contractile function in human cardiac organoids carrying ALPK3-...

James W. McNamara, Ellen B. Keen, Rebecca Sutton et al. · 2 citations
Jul 2026

LMNA p.H222P mutation causes contractile dysfunction via impaired mitochondrial calcium uptake in human cardiac laminopathy.

This work provides a paradigm for connecting gene-specific nuclear defects to mitochondrial dysfunction in inherited cardiomyopathies and highlights the MCU complex as a potential therapeutic target in LMNA-related cardiomyopathy.

M. Seguret, C. Jouve, A. Ruiz-Velasco et al. · 1 citation
Aug 2026

Vitronectin-driven amyloid deposition disrupts mitochondrial homeostasis via integrin-mediated pathway in a humanized mouse model of transthyretin cardiac amyloidosis.

Modulation of integrin signalling represents a potential complementary therapeutic strategy in ATTR-CM beyond TTR suppression and actively drives cardiac amyloid deposition, and disruption of integrin αvβ3/FAK/Akt signalling links amyloid-ECM interactions to mitochondrial dysfunction.

Zeping Qiu, Yingze Fan, J. Qin et al. · 1 citation
Open access Aug 2026

Characterization of the frameshift c.515dupC knock-in mouse model of HSPB8-associated myopathy (MFM13) and evaluation of Trehalose as autophagy-modulating therapy

These findings support the value of preclinical models for translational studies, and autophagy enhancement as a potential therapeutic strategy for HSPB8-related myopathy, and evaluated trehalose, a natural disaccharide that induces HSPB8 and enhances autophagy.

Alyaa Shmara, Lan Weiss, A. Gromova et al. · 0 citations
Open access Aug 2026

The Maine Coon Cat Harboring the MYBPC3-A31P Mutation: A Genotype-Stratified Phenotypic Characterization of Hypertrophic Cardiomyopathy

A genotype-stratified phenotypic characterization of Maine Coon cats carrying the MYBPC3-A31P mutation is provided, revealing marked gene-dose effects on cardiac structure and function and supports risk stratification and precision therapeutic strategies in human HCM.

Xiaohe Shi, Ruoxuan Li, Zi-Xuan Yang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.